AI assistant
Citius Pharmaceuticals, Inc. — Director's Dealing 2017
Aug 10, 2017
34965_dirs_2017-08-10_3fce2586-9b23-442f-a03e-66936db3cf24.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2017-08-08-06:00
Reporting Person: Mazur Leonard L (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-08-08-06:00 | Common Stock | P | 421400 | $4.125 | Acquired | 1779663 | Direct |
| 2017-08-08-06:00 | Common Stock | C | 1547067 | $3.09 | Acquired | 3326730 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-08-08-06:00 | Warrant to Purchase Common Stock | $4.125 | P | 421400 | Acquired | 2022-08-08-06:00 | Common Stock (421400) | Direct |
| 2017-08-08-06:00 | Convertible Promissory Note | $3.09 | A | 1547067 | Acquired | 2017-12-31-07:00 | Common Stock (1547067) | Direct |
| 2017-08-08-06:00 | Convertible Promissory Note | $3.09 | C | 1547067 | Disposed | 2017-12-31-07:00 | Common Stock (1547067) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrant to Purchase Common Stock | $6.15 | 2019-06-12-06:00 | Common Stock (19614) | 19614 | Direct |
| Warrant to Purchase Common Stock | $9.90 | 2019-09-30-06:00 | Common Stock (3171) | 3171 | Direct |
| Warrant to Purchase Common Stock | $9.90 | 2020-01-08-07:00 | Common Stock (4984) | 4984 | Direct |
| Warrant to Purchase Common Stock | $7.50 | 2020-08-18-06:00 | Common Stock (35211) | 35211 | Direct |
| Warrant to Purchase Common Stock | $7.50 | 2020-11-02-07:00 | Common Stock (20783) | 20783 | Direct |
| Warrant to Purchase Common Stock | $7.50 | 2020-11-20-07:00 | Common Stock (20664) | 20664 | Direct |
| Warrant to Purchase Common Stock | $7.50 | 2021-01-08-07:00 | Common Stock (13679) | 13679 | Direct |
| Warrant to Purchase Common Stock | $7.50 | 2021-03-14-07:00 | Common Stock (4210) | 4210 | Direct |
| Warrant to Purchase Common Stock | $6.15 | 2021-03-15-06:00 | Common Stock (18106) | 18106 | Direct |
| Options to Purchase Common Stock | $6.75 | 2024-09-12-06:00 | Common Stock (220000) | 220000 | Direct |
Footnotes
F1: On August 8, 2017, the Reporting Person purchased a five-year warrant to purchase 421,400 shares of the Company's common stock at an exercise price of $4.125 per share. The warrant is fully vested and exercisable six months from August 8, 2017.
F2: On August 8, 2017, the Reporting Person converted $4,710,000 of outstanding convertible promissory notes and accrued interest of $76,240 into shares of common stock at a conversion price per share of $3.09, which was 75% of the price per share paid by investors in the Company's public offering that was completed on August 8, 2017 as set forth in the terms of the convertible promissory notes.
F3: The warrant is fully vested and exercisable immediately.
F4: The option vests as to 40% of the shares of the Company's common stock on September 12, 2014 and 15% of the shares on each of September 12, 2015, March 12 and September 12, 2016 and September 12, 2017. The option was issued pursuant to the Company's 2014 Stock Incentive Plan.